keyword
MENU ▼
Read by QxMD icon Read
search

Familial combined hyperlipidemia

keyword
https://www.readbyqxmd.com/read/28822973/pai-1-levels-are-related-to-insulin-resistance-and-carotid-atherosclerosis-in-subjects-with-familial-combined-hyperlipidemia
#1
Arturo Carratala, Sergio Martinez-Hervas, Enrique Rodriguez-Borja, Esther Benito, José T Real, Guillermo T Saez, Rafael Carmena, Juan F Ascaso
Familial combined hyperlipidemia (FCH) is a primary atherogenic dyslipidemia with insulin resistance and increased cardiovascular risk. Plasminogen activator inhibitor type 1 (PAI-1) and myeloperoxidase (MPO) activity are associated with proinflammatory and atherothrombotic risk. Our aim was to study the role played by PAI-1 and MPO activity in the carotid atherosclerosis prevalence in FCH subjects. 36 FCH unrelated subjects (17 women) were matched by age and body weight with 36 healthy normolipidemic subjects (19 female)...
August 19, 2017: Journal of Investigative Medicine: the Official Publication of the American Federation for Clinical Research
https://www.readbyqxmd.com/read/28815569/glucose-dependent-leukocyte-activation-in-familial-hypercholesterolemia
#2
Natasja Koks, Marijke A de Vries, Erwin Birnie, Arash Alipour, Manuel Castro Cabezas
BACKGROUND: Leukocyte activation is an obligatory factor in the development of atherosclerosis. The postprandial situation has been associated to increased leukocyte activation in several disorders, such as type 2 diabetes mellitus and familial combined hyperlipidemia. Our study aim was to evaluate the effect of post-OGTT hyperglycemia on leukocyte activation in patients with familial hypercholesterolemia (FH). MATERIALS AND METHODS: Patients who met the diagnostic criteria for heterozygous FH and healthy volunteers were asked to undergo an oral glucose tolerance test...
August 16, 2017: European Journal of Clinical Investigation
https://www.readbyqxmd.com/read/28762942/-recommendations-of-the-european-society-of-cardiology-and-the-european-atherosclerosis-society-on-cardiovascular-disease-prevention-and-management-of-dyslipidemias-for-the-diagnosis-of-atherosclerosis-and-dyslipidemia-treatment-2016-basic-s-g
#3
M G Bubnova, V V Kukharchuk
This review summarizes the main provisions of the new, issued in 2016, recommendations of the European Society of Cardiology and Atherosclerosis Society in cooperation with the European Association on Cardiovascular Prevention and Rehabilitation on Cardiovascular disease prevention and Management of dyslipidemia. In these recommendations, the following trends can be traced distinctly: priority in primary prevention is given to non-drug methods of influence; targets of hypolipidemic therapy are identified not only for low density lipoprotein (LDL) cholesterol (CH), but also for non-high density lipoprotein (HDL) CH, especially in cases of concomitant hypertriglyceridemia...
March 2017: Kardiologiia
https://www.readbyqxmd.com/read/28744103/clinical-utility-of-evolocumab-in-the-management-of-hyperlipidemia-patient-selection-and-follow-up
#4
REVIEW
Dave L Dixon, Leo F Buckley, Cory R Trankle, Dinesh Kadariya, Antonio Abbate
Inhibition of PCSK9 is a novel therapeutic strategy aimed at reducing low-density-lipoprotein cholesterol (LDL-C) and cardiovascular risk. Evolocumab is a fully humanized monoclonal antibody that inhibits PCSK9, an enzyme that binds to LDL receptors and prevents them from recycling to the hepatocyte surface. Clinical trials have demonstrated 50%-70% reductions in LDL-C with evolocumab when used in combination with statin therapy. The recent FOURIER trial demonstrated that evolocumab further reduces cardiovascular events, but not mortality, in high-risk patients already receiving statin therapy...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28681648/statin-therapy-and-risk-of-diabetes-mellitus-in-aging-patients-with-heterozygous-familial-hypercholesterolemia-or-familial-combined-hyperlipidemia-a-10-year-follow-up
#5
Ioannis Skoumas, Nikolaos Ioakeimidis, Charalambos Vlachopoulos, Christina Chrysohoou, Christos Michalakeas, Christos Georgakopoulos, Vicky Katsi, Demosthenes Panagiotakos, Dimitrios Tousoulis
We assessed the incidence of diabetes mellitus (DM) in patients with heterozygous familial hypercholesterolemia (HeFH) and familial combined hyperlipidemia (FCH) treated with statins. Participants (n = 280) of mean age 59 ± 5 years were included (90 patients with HeFH, 112 patients with FCH, and 78 aged-matched participants). The median statin intensity treatment product (statin intensity in arbitrary equivalence units × duration of statin therapy in months) was 119 and 85 for patients with HeFH and FCH, respectively, at 10-year follow-up...
January 1, 2017: Angiology
https://www.readbyqxmd.com/read/28651396/-interaction-between-family-history-of-diabetes-and-hyperlipidemia-on-risk-of-diabetes-in-population-with-normotension-in-harbin-a-cross-sectional-study
#6
C D Bao, B Sun, L Lan, H Qiao, D F Zhang, X Y Liu, J Wang, Y S Zhao
Objective: To explore the interaction between family history of diabetes and hyperlipidemia on the risk of diabetes in population with normotension. Methods: A multistage stratified probability random sampling was conducted to select a representative sample of urban residents aged 20-74 years in Harbin. A total of 376 diabetes patients with normotension and 3 692 residents with normal blood pressure, normal fasting glucose, and normal 2 hours glucose from OGTT were surveyed. The interaction was evaluated by using crossover analysis and additive model...
May 10, 2017: Zhonghua Liu Xing Bing Xue za Zhi, Zhonghua Liuxingbingxue Zazhi
https://www.readbyqxmd.com/read/28391878/autosomal-dominant-familial-dysbetalipoproteinemia-a-pathophysiological-framework-and-practical-approach-to-diagnosis-and-therapy
#7
REVIEW
Charlotte Koopal, A David Marais, Jan Westerink, Frank L J Visseren
Familial dysbetalipoproteinemia (FD) is a genetic disorder of lipoprotein metabolism associated with an increased risk for premature cardiovascular disease. In about 10% of the cases, FD is caused by autosomal dominant mutations in the apolipoprotein E gene (APOE). This review article provides a pathophysiological framework for autosomal dominant FD (ADFD) and discusses diagnostic challenges and therapeutic options. The clinical presentation and diagnostic work-up of ADFD are illustrated by two cases: a male with premature coronary artery disease and a p...
January 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/28321018/coronary-artery-disease-in-premenopausal-and-postmenopausal-women
#8
COMPARATIVE STUDY
Lu Yihua, Jiang Yun, Zhao Dongshen
The purpose was to determine the differences between premenopausal and postmenopausal coronary artery disease (CAD) risk factors, clinical manifestation, cardiovascular features, rates of recurrence, and influencing factors.Premenopausal (n = 57) and postmenopausal (n = 178) CAD women hospitalized during the same period were enrolled. All patients were followed-up, and the combined recurrence of major adverse cardiovascular events was recorded as the clinical outcome. Differences were compared between the 2 groups...
April 6, 2017: International Heart Journal
https://www.readbyqxmd.com/read/28242176/2017-taiwan-lipid-guidelines-for-high-risk-patients
#9
REVIEW
Yi-Heng Li, Kwo-Chang Ueng, Jiann-Shing Jeng, Min-Ji Charng, Tsung-Hsien Lin, Kuo-Liong Chien, Chih-Yuan Wang, Ting-Hsing Chao, Ping-Yen Liu, Cheng-Huang Su, Shih-Chieh Chien, Chia-Wei Liou, Sung-Chun Tang, Chun-Chuan Lee, Tse-Ya Yu, Jaw-Wen Chen, Chau-Chung Wu, Hung-I Yeh
In Taiwan, the prevalence of hyperlipidemia increased due to lifestyle and dietary habit changes. Low density lipoprotein cholesterol (LDL-C) and non-high density lipoprotein cholesterol (non-HDL-C) are all significant predicting factors of coronary artery disease in Taiwan. We recognized that lipid control is especially important in patients with existed atherosclerotic cardiovascular diseases (ASCVD), including coronary artery disease (CAD), ischemic stroke and peripheral arterial disease (PAD). Because the risk of ASCVD is high in patients with diabetes mellitus (DM), chronic kidney disease (CKD) and familial hypercholesterolemia (FH), lipid control is also necessary in these patients...
April 2017: Journal of the Formosan Medical Association, Taiwan Yi Zhi
https://www.readbyqxmd.com/read/28215923/association-between-the-presence-carotid-artery-plaque-and-cardiovascular-events-in-patients-with-genetic-hypercholesterolemia
#10
Ana M Bea, Fernando Civeira, Estíbaliz Jarauta, Itziar Lamiquiz-Moneo, Sofía Pérez-Calahorra, Victoria Marco-Benedí, Ana Cenarro, Rocío Mateo-Gallego
INTRODUCTION AND OBJECTIVES: The equations used in the general population to calculate cardiovascular risk are not useful in genetic hypercholesterolemia (GH). Carotid plaque detection has proved useful in cardiovascular prediction and risk reclassification but there have been no studies of its usefulness in GH. The aim of this study was to determine the association between the presence of carotid artery plaque and the occurrence of cardiovascular events in patients with GH. METHODS: This study included 1778 persons with GH...
February 16, 2017: Revista Española de Cardiología
https://www.readbyqxmd.com/read/28098593/familial-dysbetalipoproteinemia-an-underdiagnosed-lipid-disorder
#11
Charlotte Koopal, A David Marais, Frank L J Visseren
PURPOSE OF REVIEW: To review pathophysiological, epidemiological and clinical aspects of familial dysbetalipoproteinemia; a model disease for remnant metabolism and remnant-associated cardiovascular risk. RECENT FINDINGS: Familial dysbetalipoproteinemia is characterized by remnant accumulation caused by impaired remnant clearance, and premature cardiovascular disease. Most familial dysbetalipoproteinemia patients are homozygous for apolipoprotein ε2, which is associated with decreased binding of apolipoprotein E to the LDL receptor...
April 2017: Current Opinion in Endocrinology, Diabetes, and Obesity
https://www.readbyqxmd.com/read/28097454/in-vitro-cytogenetic-toxicity-of-bezafibrate-in-human-peripheral-blood-lymphocytes
#12
M Topaktas, N E Kafkas, S Sadighazadi, E S Istifli
Bezafibrate (BF) is a peroxisome proliferator-activated receptor (PPAR) agonist used as a lipid-lowering agent to treat both the familial or acquired combined forms of hyperlipidemia. BF is the only available fibrate drug that acts on all PPAR subtypes of α, β, and δ. Although there are studies that indicate a genotoxic potential associated with the use of fibrates, to our knowledge, the genotoxicity of BF in human peripheral blood lymphocytes has not been studied. In the present study, the genotoxic potential of BF was evaluated using chromosome aberration (CA) and micronucleus (MN) assays in peripheral blood lymphocytes of healthy human subjects...
August 2017: Cytotechnology
https://www.readbyqxmd.com/read/28030378/does-lifestyle-contribute-to-disease-severity-in-patients-with-inherited-lipid-disorders
#13
Benoit J Arsenault, Nicolas Perrot, Patrick Couture
PURPOSE OF REVIEW: Patients with familial hypercholesterolemia, familial combined hyperlipidemia and hyperlipoprotein(a) are at high cardiovascular risk. Increasing evidence suggest that lifestyle-related risk factors such as physical inactivity, and poor diet quality could influence cardiovascular risk in these patients. Our objective is to review the evidence that supports the role of lifestyle-related factors in the prediction of cardiovascular risk in patients with inherited lipid disorders...
April 2017: Current Opinion in Lipidology
https://www.readbyqxmd.com/read/27919349/familial-combined-hyperlipidemia-and-hyperlipoprotein-a-as-phenotypic-mimics-of-familial-hypercholesterolemia-frequencies-associations-and-predictions
#14
Katrina L Ellis, Jing Pang, Dick C Chan, Amanda J Hooper, Damon A Bell, John R Burnett, Gerald F Watts
BACKGROUND: A significant proportion of index cases presenting with phenotypic familial hypercholesterolemia (FH) are not found to have a pathogenic mutation and may have other inherited conditions. OBJECTIVES: Familial combined hyperlipidemia (FCHL) and elevated lipoprotein(a) [Lp(a)] may mimic FH, but the frequency and correlates of these disorders among mutation-negative FH patients have yet to be established. METHODS: The frequency of FCHL and elevated Lp(a) was investigated in 206 FH mutation-negative index cases attending a specialist lipid clinic...
November 2016: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/27812268/strawberry-pink-blood
#15
Jayashree D Kulkarni, Puneeta Bhatia, Sanjay A Pai
Blood need not always be red. We report a case of a 3 month old boy whose blood was strawberry pink before centrifugation and white (profusely lipemic) after centrifugation. The differential diagnosis was familial hypercholesterolemia or familial combined hyperlipidemia.
December 2016: Indian Journal of Hematology & Blood Transfusion
https://www.readbyqxmd.com/read/27274264/pcsk9-inhibition-in-the-management-of-hyperlipidemia-focus-on-evolocumab
#16
REVIEW
Dirk J Blom, Ricardo Dent, Rita C Castro, Peter P Toth
Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases low-density lipoprotein cholesterol (LDL-C) concentrations through interference with normal physiologic hepatic LDL receptor (LDLR) recycling. Inhibiting PCSK9 results in improved LDLR recycling, increased LDLR availability on hepatocyte cell surfaces, and reduced blood LDL-C levels, making PCSK9 inhibition a novel therapeutic strategy for managing hypercholesterolemia. Monoclonal antibodies directed against PCSK9 have been developed for this purpose...
2016: Vascular Health and Risk Management
https://www.readbyqxmd.com/read/27227539/the-contribution-of-gwas-loci-in-familial-dyslipidemias
#17
Pietari Ripatti, Joel T Rämö, Sanni Söderlund, Ida Surakka, Niina Matikainen, Matti Pirinen, Päivi Pajukanta, Antti-Pekka Sarin, Susan K Service, Pirkka-Pekka Laurila, Christian Ehnholm, Veikko Salomaa, Richard K Wilson, Aarno Palotie, Nelson B Freimer, Marja-Riitta Taskinen, Samuli Ripatti
Familial combined hyperlipidemia (FCH) is a complex and common familial dyslipidemia characterized by elevated total cholesterol and/or triglyceride levels with over five-fold risk of coronary heart disease. The genetic architecture and contribution of rare Mendelian and common variants to FCH susceptibility is unknown. In 53 Finnish FCH families, we genotyped and imputed nine million variants in 715 family members with DNA available. We studied the enrichment of variants previously implicated with monogenic dyslipidemias and/or lipid levels in the general population by comparing allele frequencies between the FCH families and population samples...
May 2016: PLoS Genetics
https://www.readbyqxmd.com/read/27208733/increased-thioredoxin-levels-are-related-to-insulin-resistance-in-familial-combined-hyperlipidaemia
#18
Sergio Martinez-Hervas, Ana Artero, Juncal Martinez-Ibañez, Mari C Tormos, Herminia Gonzalez-Navarro, Antonia Priego, Jose F Martinez-Valls, Guillermo T Saez, Jose T Real, Rafael Carmena, Juan F Ascaso
BACKGROUND: Thioredoxins (TRX) are major cellular protein disulphide reductases that are critical for redox regulation. Oxidative stress and inflammation play promoting roles in the genesis and progression of atherosclerosis, but until now scarce data are available considering the influence of TRX activity in familial combined hyperlipidaemia (FCH). Since FCH is associated with high risk of cardiovascular disease, the objective of the present study was to assess oxidative stress status in FCH patients, and evaluate the influence of insulin resistance (IR)...
July 2016: European Journal of Clinical Investigation
https://www.readbyqxmd.com/read/27089599/-new-guidelines-for-screening-and-management-of-familial-dyslipidemia
#19
Nathalie Brun, Carole E Aubert, David Nanchen, Nicolas Rodondi
Familial dyslipidemia, a frequent genetic cause of premature cardiovascular disease, is still underdiagnosed and undertreated. According to recent European studies, the prevalence of familial hypercholesterolemia is higher than previously suspected and reaches 1/200-300 persons, while familial combined hyperlipidemia affects 1-3% of the population. Screening is important, as familial dyslipidemia often leads to cardiovascular event before 60 years of age, and usual scores of risk are not appropriate for these patients...
March 2, 2016: Revue Médicale Suisse
https://www.readbyqxmd.com/read/27069966/prevalence-and-predictors-of-atherosclerotic-renal-artery-stenosis-in-hypertensive-patients-undergoing-simultaneous-coronary-and-renal-artery-angiography-a-cross-sectional-study
#20
Babak Payami, Mehrian Jafarizade, Seyed Seifollah Beladi Mousavi, Shahab-Aldin Sattari, Forough Nokhostin
INTRODUCTION: According to the non-specific presentation of atherosclerotic renal artery stenosis (ARAS), this disease is usually an under-diagnosed in clinical conditions. OBJECTIVES: The aim of the presence study was to evaluate the prevalence of renal artery stenosis (RAS) and its related risk factors in hypertensive patients undergoing coronary angiography. PATIENTS AND METHODS: In a cross-sectional study, between March 2009 and October 2010, all of hypertensive patients candidate for diagnostic cardiac catheterization, underwent nonselective renal angiography before completion of their coronary angiography procedure...
2016: Journal of Renal Injury Prevention
keyword
keyword
62359
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"